Cannabinoids and pain management;Les cannabinoïdes et le contrôle de la douleur

Canadian Journal of Anesthesia

Volumn 53, Issue 8, 2006, Pages 743-746

  Hung, Orlando ^a,b   Lynch, Mary E ^b   Clark, Alexander J ^c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; CODEINE; DRONABINOL; ENDOCANNABINOID; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NABILONE; OPIATE; OPIATE RECEPTOR; PLACEBO;

ANALGESIC ACTIVITY; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; CLINICAL TRIAL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ISOLATION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; EDITORIAL; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; LIPOPHILICITY; MONOAMINERGIC SYSTEM; NEUROPATHIC PAIN; NONHUMAN; PAIN; PAIN ASSESSMENT; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEIN FUNCTION; SAMPLE SIZE; SCORING SYSTEM; STANDARDIZATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33748862387     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03022788     Document Type: Editorial

References (19)

1. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646-7.
2. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 101-21.
3. Lynch ME. Preclinical science regarding cannabinoids as analgesics: an overview. Pain Res Manag 2005; 10(Suppl A): 7A-14A.
4. Walker JM, Strangman NM, Huang SM. Cannabinoids and pain. Pain Res Manag 2001; 6: 74-9.
5. Beaulieu P. Effects of nabione, a synthetic cannabinoid, on postoperative pain. Can J Anesth 2006; 53: 769-75.
6. Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 1981; 21(8-9 Suppl): 320S-6S.
7. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323: 13-6.
8. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329: 253.
9. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre rendomised placebo-controlled trial. Lancet 2003; 362: 1517-26.
10. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study:safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005; 76: 1664-9.
11. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004; 112: 299-306.
12. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65: 812-9.
13. Lynch ME, Watson CP. The pharmacotherapy of chronic pain: a review. Pain Res Manag 2006; 11: 11-38.
14. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain 2003; 102: 211-6.
15. Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME. Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004; 62: 2098-2100.
16. Ogborne AC, Smart RG. Cannabis users in the general Canadian population. Subst Use Misuse 2000; 35: 301-11.
17. Ogborne AC, Smart RG, Weber T, Birchmore-Tmney C. Who is using cannabis as a medicine and why: an exploratory study. J Psychoactive Drugs 2000; 32: 435-43.
18. Burstein SH. The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential. Pharmacol Ther 1999; 82: 87-96
19. Sumariwalla PF, Gallily L, Tchilibon S, Fride E, Mechoulam R, Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum 2004; 50: 985-98.